Longdaysin

• Description:

  Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC50s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319

• Target:

  Casein Kinase; CDK; ERK; Wnt

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; MAPK/ERK Pathway; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/longdaysin.html

• Purity:

  99.83

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  FC(F)(F)C1=CC=CC(CNC2=NC=NC3=C2N=CN3C(C)C)=C1

• Molecular Formula:

  C16H16F3N5

• Molecular Weight:

  335.33

• Precautions:

  H315, H319

• References & Citations:

  [1]Griffett K, et al. The mammalian clock and chronopharmacology. Bioorganic & Medicinal Chemistry Letters, 2013, 23 (7) :1929-1934..|[2]Hirota T, et al. High-throughput chemical screen identifies a novel potent modulator of cellular circadian rhythms and reveals CKIα as a clock regulatory kinase. PLoS Biol. 2010 Dec 14;8 (12) :e1000559.|[3]Xiong Y, et al. Longdaysin inhibits Wnt/β-catenin signaling and exhibits antitumor activity against breast cancer. Onco Targets Ther. 2019 Feb 5;12:993-1005.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK7; CK1; ERK2

• CAS Number:

  [1353867-91-0]